Bringing the Future of Gene Therapy into Focus

We are opening opportunities for treating debilitating diseases with limited options.

Apertura: Expanding the Promise of Gene Therapy to a Broader Set of Diseases

Apertura is uniquely positioned to develop genetic medicines by simultaneously engineering AAV capsids, regulatory elements, and payloads.

Determined to Overcome the Current Limitations of AAV Gene Therapy

Issues in cellular access, gene expression, pre-existing immunity, and manufacturability have limited the impact of gene therapy. Today we understand more about these limitations and how to overcome them by taking advantage of recent advances in vector biology, protein engineering, machine learning, epigenetic profiling, next generation sequencing and DNA synthesis.

The Multidisciplinary Team Engineering the Next Gene Therapy Frontier

Our team includes leaders in vector engineering, gene regulation, machine learning, and the treatment of rare diseases. Each member shares Apertura’s dedication and commitment to advancing gene therapy discoveries so that we can drive the next breakthroughs across an entire spectrum of genetic disorders.

Partnering for Accelerated Impact

We are committed to growing the field of gene therapy and maximizing our impact through partnerships. We welcome opportunities to collaborate with corporate and academic partners, patients, and disease foundations. Together, let’s accelerate the development of transformative gene therapies for more patients.

News & Resources

Apertura Appoints Gene Therapy Executive Joseph La Barge as Chief Executive Officer

La Barge joins Apertura with over 20 years of experience in building and operating life-science companies. Most recently, he served as Chief Business Officer of Spark Therapeutics, where he was one of the earliest employees and led the growth of the company through its acquisition by Roche for $4.8 billion in December 2019.

Apertura Announces Fit4Function AAV Capsid Engineering Platform and In Vivo Proof-of-Concept Data to Be Presented at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Apertura Gene Therapy announced that its academic collaborators will present findings on the Fit4Function AAV capsid engineering platform and non-human primate proof-of-concept data at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), being held virtually and in Washington, D.C., from May 16–19, 2022.

Apertura Gene Therapy Launches with $67M Series A Financing from Deerfield and an Innovative Technology Platform to Develop Genetic Medicines  

Founded on platform technologies developed by Broad Institute of MIT and Harvard and Harvard Medical School Investigators

Apertura Logo